Early results from Moderna’s coronavirus vaccine trial provide first insight into our immune system’s ability to be trained into producing antibodies
A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the new coronavirus, in Cambridge, Massachusetts, US, May 18, 2020.
The study, which was not designed to prove the vaccine works, offered an early glimmer of hope that it could provide protection against the virus. Moderna's vaccine has gotten the green light to start the second stage of human testing, and last week, US regulators gave the vaccine "fast-track" status to speed up the regulatory review.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Moderna coronavirus vaccine releases first human trial results - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Weiterlesen »
Stocks rebound as positive Moderna vaccine trial boosts optimism for economic recoveryStocks bounced back Monday on optimism the U.S. economy may start to recover from the coronavirus pandemic after drugmaker Moderna released promising early results for a vaccine.
Weiterlesen »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Weiterlesen »
Business, government operate under new rules, market ralliesNEW: Shares of Moderna jumped 25%, and U.S. markets surged higher, after the biotech company said early data from testing of its coronavirus vaccine showed promising signs.
Weiterlesen »
New Coronavirus Vaccine Candidate Shows Promise In Early, Limited TrialModerna, a drug manufacturer, is reporting early successes in a trial for a coronavirus vaccine that produces antibodies to fight the virus and give some immunity. Now it plans to increase its study from 45 participants to 600 — half over the age of 55.
Weiterlesen »
Coronavirus live updates: 'Positive' vaccine data lifts Moderna stock; Spain's GDP could fall more than 9.5%Covid-19 has now infected more than 4.7 million people around the world as of Monday, killing at least 315,496 people.
Weiterlesen »